AR028605A1 - Compuesto quimico - Google Patents

Compuesto quimico

Info

Publication number
AR028605A1
AR028605A1 ARP010102431A ARP010102431A AR028605A1 AR 028605 A1 AR028605 A1 AR 028605A1 AR P010102431 A ARP010102431 A AR P010102431A AR P010102431 A ARP010102431 A AR P010102431A AR 028605 A1 AR028605 A1 AR 028605A1
Authority
AR
Argentina
Prior art keywords
chemical compound
chemical
compound
Prior art date
Application number
ARP010102431A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR028605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR028605A1 publication Critical patent/AR028605A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
ARP010102431A 2000-06-02 2001-05-22 Compuesto quimico AR028605A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013488.2A GB0013488D0 (en) 2000-06-02 2000-06-02 Chemical compound
SE0002102A SE0002102D0 (sv) 2000-06-02 2000-06-06 Chemical compound

Publications (1)

Publication Number Publication Date
AR028605A1 true AR028605A1 (es) 2003-05-14

Family

ID=26244413

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102431A AR028605A1 (es) 2000-06-02 2001-05-22 Compuesto quimico

Country Status (36)

Country Link
US (6) US7067663B2 (es)
EP (1) EP1299390B1 (es)
JP (1) JP4947870B2 (es)
KR (2) KR100814229B1 (es)
CN (3) CN101143864A (es)
AR (1) AR028605A1 (es)
AT (1) ATE386039T1 (es)
AU (4) AU2001262876B2 (es)
BG (1) BG65866B1 (es)
BR (1) BR0111319A (es)
CA (1) CA2408914C (es)
CY (1) CY1108101T1 (es)
CZ (3) CZ302644B6 (es)
DE (1) DE60132776T2 (es)
DK (1) DK1299390T3 (es)
EE (1) EE05223B1 (es)
ES (1) ES2299487T3 (es)
GB (1) GB0013488D0 (es)
HK (1) HK1053122A1 (es)
HU (1) HU229281B1 (es)
IL (3) IL152776A0 (es)
IS (1) IS2600B (es)
MX (2) MXPA02011793A (es)
MY (1) MY131942A (es)
NO (1) NO324266B1 (es)
NZ (1) NZ522637A (es)
PL (3) PL210375B1 (es)
PT (1) PT1299390E (es)
RU (1) RU2295526C2 (es)
SE (1) SE0002102D0 (es)
SI (1) SI1299390T1 (es)
SK (1) SK286845B6 (es)
TW (1) TWI285203B (es)
UA (1) UA73182C2 (es)
WO (1) WO2001092263A1 (es)
ZA (1) ZA200209068B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0401001D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0400873D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
GB0615620D0 (en) * 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
GB0615619D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab Chemical process for preparation of intermediates
CA2668180A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
CA2734454C (en) 2008-09-09 2016-09-13 Astrazeneca Ab A process for preparing [1s-[1-alpha,2-alpha,3-beta(1s*,2r*)5-beta]]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3h-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol and to its intermediates
JP5580741B2 (ja) 2008-09-19 2014-08-27 武田薬品工業株式会社 含窒素複素環化合物およびその用途
EP2250127A4 (en) * 2009-03-02 2011-04-06 Calera Corp SYSTEMS AND METHODS FOR REMOVAL OF MULTI-POLLUTANTS FROM GASEOUS CURRENTS
CA2768043A1 (en) 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
EP2305376A1 (en) 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
EP2560939A2 (en) 2010-04-20 2013-02-27 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
EP2588441A2 (en) * 2010-06-30 2013-05-08 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
JP2014501756A (ja) 2010-12-20 2014-01-23 アクタビス・グループ・ピーティーシー・イーエイチエフ トリアゾロ［４，５−ｄ］ピリミジン誘導体及びその中間体の新規調整方法
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CN102731467B (zh) * 2011-04-15 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的中间体及制备替卡格雷的方法
TWI537256B (zh) * 2011-05-13 2016-06-11 阿斯特捷利康公司 製備［（３aＳ,４Ｒ,６Ｓ,６aＲ）－６－羥基－２,２－二甲基四氫－３aＨ－環戊并［d］［１,３］二氧戊環－４－基］胺甲酸苄基酯之方法及該方法中的中間體
EP2721018A1 (en) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
EP2570405A1 (en) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
US9221829B2 (en) 2011-09-14 2015-12-29 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
CN104024230B (zh) * 2011-10-27 2016-05-04 力奇制药公司 ***并嘧啶化合物的合成
EP2586773A1 (en) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
AU2012343928A1 (en) 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
CA2859580A1 (en) 2011-12-23 2013-06-27 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
WO2013144295A1 (en) 2012-03-30 2013-10-03 Sandoz Ag Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
WO2013150495A2 (en) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2013163892A1 (en) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
EP2666771A1 (en) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthesis of Aminocyclopentanetriol Derivatives
CN104520278A (zh) * 2012-08-06 2015-04-15 埃南蒂亚有限公司 ***并嘧啶碳核苷的中间体的制备方法
CN103588674B (zh) * 2012-08-14 2015-02-11 上海医药工业研究院 一种具有光学活性的环丙烷酰阱化合物、其制备和应用
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN104341402B (zh) * 2013-07-23 2018-04-27 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷中间体的方法
WO2014086291A1 (zh) * 2012-12-06 2014-06-12 博瑞生物医药技术(苏州)有限公司 一种制备替卡格雷的方法及其中间体
CN103848834B (zh) * 2012-12-06 2017-09-22 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷的方法及其中间体
IN2012MU03723A (es) 2012-12-31 2015-07-10 Megafine Pharma P Ltd
CN103936767B (zh) * 2013-01-23 2016-08-03 上海医药工业研究院 一种制备化合物(1r,2s,6s,7s)-4,4-二甲基-9-苯甲基-3,5,8-三氧杂-9-氮杂三环[5.2.1.02.6]葵烷的方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN107573333B (zh) 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CN103275056B (zh) * 2013-05-24 2015-06-17 浙江普洛医药科技有限公司 一种替卡格雷中间体的制备方法
EP3004113A2 (en) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN103275087A (zh) * 2013-06-28 2013-09-04 南京工业大学 一种三氮唑并嘧啶类衍生物及其制备方法
CN104059069B (zh) * 2013-08-22 2016-08-10 北京康立生医药技术开发有限公司 一种替卡格雷的制备方法
CN104592237A (zh) * 2013-10-31 2015-05-06 徐州万邦金桥制药有限公司 一种抗凝血药替格瑞洛的合成方法
CN103588750B (zh) * 2013-11-07 2014-11-26 苏州明锐医药科技有限公司 替卡格雷中间体的制备方法
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN103588712B (zh) * 2013-11-08 2016-06-08 南京欧信医药技术有限公司 一种嘧啶类化合物及其制备方法、和应用
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104744424B (zh) * 2013-12-27 2018-12-25 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CN103923020A (zh) * 2014-04-02 2014-07-16 黄河三角洲京博化工研究院有限公司 一种2-丙硫基-4,6-二氯-5-氨基嘧啶的制备方法
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
WO2015193165A1 (en) 2014-06-18 2015-12-23 Flamma Spa Process for the preparation of triazolo[4,5-d] pyrimidine cyclopentane compounds
WO2016001851A1 (en) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN104193748A (zh) * 2014-08-14 2014-12-10 严白双 一种替卡格雷的合成方法
WO2016030704A1 (en) * 2014-08-30 2016-03-03 Cipla Limited Solid form of intermediate of ticagrelor
CN105801583A (zh) * 2014-12-31 2016-07-27 徐州万邦金桥制药有限公司 一种替格瑞洛的纯化方法
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
WO2016117852A2 (ko) * 2015-01-22 2016-07-28 동아에스티 주식회사 티카그렐러 제조방법 및 이를 위한 신규한 중간체
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种***并嘧啶衍生物及其应用
CN105153167B (zh) * 2015-09-06 2017-09-19 惠州信立泰药业有限公司 一种替格瑞洛结晶及含有该结晶的药物组合物
CN105198864B (zh) * 2015-10-21 2018-11-06 华仁药业股份有限公司 一种环戊基嘧啶化合物的无溶剂制备方法
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
CN105669681A (zh) * 2016-04-11 2016-06-15 成都华宇制药有限公司 一种替格瑞洛的合成方法
CN106543191B (zh) * 2016-10-28 2019-03-01 天津红日药业股份有限公司 一种替格瑞洛制备工艺
CN107337675A (zh) * 2017-06-03 2017-11-10 湖南天济草堂制药股份有限公司 一种制备替格瑞洛的改进方法
CN107382953A (zh) * 2017-07-25 2017-11-24 安徽诺全药业有限公司 一种制备多取代环戊烷衍生物的方法
CN108689984B (zh) * 2018-05-02 2019-09-20 淮阴工学院 一种替格瑞洛中间体的生物合成方法及其中间体
CN110894184B (zh) * 2019-11-25 2022-02-18 安徽一帆香料有限公司 一种基于绿色环保的替格瑞洛中间体的制备方法
EP3919497A1 (en) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of ticagrelor
CN112457316B (zh) * 2020-11-05 2022-04-12 南通常佑药业科技有限公司 一种应用连续流反应技术制备替卡格雷高级中间体的方法
CN112724119B (zh) * 2020-12-30 2022-05-03 江苏恒沛药物科技有限公司 一种替卡格雷关键中间体的合成方法
CN115160320B (zh) * 2022-06-27 2024-05-07 南通常佑药业科技有限公司 一种手性嘧啶并***类替格瑞洛的制备方法
CN115785058B (zh) * 2022-12-09 2024-05-03 广州康瑞泰药业有限公司 一种合成替格瑞洛五元环中间体的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3040406A1 (de) * 1980-10-27 1982-05-27 Degussa Ag, 6000 Frankfurt Verfahren zur gewinnung von n-tert-alkylaminen und ameisensaeureestern
GB8916477D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
CA2021784A1 (en) * 1989-07-24 1991-01-25 Alan D. Borthwick Cyclopentane derivatives
US5654285A (en) * 1991-04-06 1997-08-05 Astra Pharmaceuticals Limited ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
CA2107667A1 (en) * 1991-04-06 1992-10-07 Anthony Howard Ingall Atp analogues
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
EP0840740B1 (en) 1995-07-11 2002-05-02 AstraZeneca AB New inhibitors of platelet aggregation
JP4125790B2 (ja) * 1996-12-20 2008-07-30 アストラゼネカ・アクチエボラーグ トリアゾロ［４，５−ｄ］ピリミジニル誘導体および医薬としてのその使用
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
IL137812A0 (en) 1998-02-17 2001-10-31 Astrazeneca Uk Ltd Novel triazolo (4,5-d) pyrimidine compounds
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CZ20002947A3 (cs) * 1999-02-05 2000-11-15 Astrazeneca Uk Limited Nové triazolo(4,5-d)pyrimidiny, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound

Also Published As

Publication number Publication date
CZ303162B6 (cs) 2012-05-09
CN1432017A (zh) 2003-07-23
CA2408914A1 (en) 2001-12-06
MY131942A (en) 2007-09-28
AU2010200461B2 (en) 2011-08-18
ZA200209068B (en) 2003-12-02
CA2408914C (en) 2009-12-29
EE200200669A (et) 2004-06-15
US8273879B2 (en) 2012-09-25
BR0111319A (pt) 2003-06-03
CZ20023919A3 (cs) 2003-05-14
US7381828B2 (en) 2008-06-03
ATE386039T1 (de) 2008-03-15
IS6614A (is) 2002-11-14
SK286845B6 (sk) 2009-06-05
EE05223B1 (et) 2009-10-15
US20110218330A1 (en) 2011-09-08
PT1299390E (pt) 2008-04-17
AU2001262876B2 (en) 2007-03-01
AU2007200776A1 (en) 2007-03-15
NO324266B1 (no) 2007-09-17
GB0013488D0 (en) 2000-07-26
ES2299487T3 (es) 2008-06-01
US20100004444A1 (en) 2010-01-07
DK1299390T3 (da) 2008-05-26
AU2007200776B2 (en) 2009-11-19
US20060041132A1 (en) 2006-02-23
BG107333A (bg) 2003-07-31
US20070049755A1 (en) 2007-03-01
JP2003535093A (ja) 2003-11-25
KR20080003458A (ko) 2008-01-07
KR20030007828A (ko) 2003-01-23
PL212128B1 (pl) 2012-08-31
RU2295526C2 (ru) 2007-03-20
US20030148888A1 (en) 2003-08-07
PL210375B1 (pl) 2012-01-31
KR100814229B1 (ko) 2008-03-17
HK1053122A1 (en) 2003-10-10
SE0002102D0 (sv) 2000-06-06
HUP0302345A3 (en) 2007-10-29
NO20025719L (no) 2003-02-03
JP4947870B2 (ja) 2012-06-06
MX336939B (es) 2016-02-08
EP1299390A1 (en) 2003-04-09
HU229281B1 (en) 2013-10-28
US7067663B2 (en) 2006-06-27
MXPA02011793A (es) 2003-04-10
NZ522637A (en) 2004-09-24
DE60132776T2 (de) 2009-02-12
CN100354268C (zh) 2007-12-12
IL225893A (en) 2015-08-31
DE60132776D1 (de) 2008-03-27
IS2600B (is) 2010-04-15
CN1200940C (zh) 2005-05-11
US20080234481A1 (en) 2008-09-25
TWI285203B (en) 2007-08-11
WO2001092263A1 (en) 2001-12-06
BG65866B1 (bg) 2010-03-31
EP1299390B1 (en) 2008-02-13
IL152776A0 (en) 2003-06-24
CZ302644B6 (cs) 2011-08-10
KR100802884B1 (ko) 2008-02-13
PL392726A1 (pl) 2010-12-06
PL211318B1 (pl) 2012-05-31
PL359183A1 (en) 2004-08-23
CN1680340A (zh) 2005-10-12
NO20025719D0 (no) 2002-11-28
HUP0302345A2 (hu) 2003-11-28
SK16832002A3 (sk) 2003-06-03
IL152776A (en) 2013-06-27
AU2010200461A1 (en) 2010-02-25
PL392725A1 (pl) 2010-12-06
IL225893A0 (en) 2013-06-27
CZ302645B6 (cs) 2011-08-10
CY1108101T1 (el) 2014-02-12
SI1299390T1 (sl) 2008-06-30
AU6287601A (en) 2001-12-11
CN101143864A (zh) 2008-03-19
UA73182C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
AR028605A1 (es) Compuesto quimico
AR028414A1 (es) Compuestos quimicos
DK1326832T3 (da) Kemiske forbindelser
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
NO20024774D0 (no) Kjemiske forbindelser
NO20032829L (no) Kjemiske forbindelser
NO20021637L (no) Kjemikalske forbindelser
AR027983A1 (es) Novedosos compuestos
NO20030628D0 (no) Kjemiske forbindelser
IS6657A (is) Ný efnasambönd
ID29755A (id) Senyawa-senyawa organosilikon
ATE372338T1 (de) Deshalogenverbindungen
AR028220A1 (es) Novedosos compuestos
NO20031837D0 (no) Kalsilytiske forbindelser
NO20030303L (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
TR200100070A3 (tr) Bilesim
AR028399A1 (es) Nuevos compuestos
SE0003664D0 (sv) Chemical compounds
AR028304A1 (es) Compuestos quimicos
SE0004925D0 (sv) Kemiska föreningar
SE0104262D0 (sv) Chemical compound
SE0103797D0 (sv) Chemical compounds
SE0003477D0 (sv) Compounds

Legal Events

Date Code Title Description
FG Grant, registration